Related Experiment Videos
[Adenosine triphosphate and supraventricular tachycardia]
1III. interná klinika Fakultnej nemocnice L. Pasteura.
Vnitrni Lekarstvi
|November 1, 1994
Summary
Intravenously administered adenosine triphosphate (ATP) effectively converts reentry supraventricular tachycardias to sinus rhythm by blocking the AV node. However, ATP did not eliminate other tachycardia forms and may have proarrhythmic effects on the atria.
Area of Science:
- Cardiology
- Electrophysiology
- Pharmacology
Context:
- Supraventricular tachycardias (SVT) are common arrhythmias.
- Adenosine triphosphate (ATP) is used to treat certain SVTs.
- Differentiating SVT types is crucial for effective treatment.
Purpose:
- To evaluate the efficacy of intravenously administered adenosine triphosphate (ATP) in converting various forms of supraventricular tachycardia (SVT) to sinus rhythm.
- To assess the diagnostic and therapeutic potential of ATP in SVT management.
Summary:
- Twenty-one patients with SVT underwent electrophysiological examination.
- Intravenous ATP (0.3 mg/kg) was administered during tachycardia.
- ATP successfully converted AV nodal reentry tachycardia (AVNRT) and atrioventricular reentry tachycardia (AVRT) to sinus rhythm.
- ATP was ineffective in converting atrial fibrillation (AF), atrial flutter (AFL), and automatic atrial tachycardia (AAT).
- ATP's antiarrhythmic effect is attributed to blocking reentry circuits in the AV node.
- A proarrhythmic effect on the atria was observed.
- ATP's effect on abnormal automaticity was not confirmed.
Impact:
- ATP demonstrates specific efficacy in terminating reentry-based SVTs.
- This study clarifies ATP's role in SVT management, distinguishing between responsive and unresponsive arrhythmias.
- Findings support ATP's use for AVNRT and AVRT, while cautioning against its use in other SVT forms.
- Understanding ATP's mechanism and limitations improves clinical decision-making in arrhythmia treatment.